Product Description
a Cord blood-derived T-regulatory cell product for patients with bone marrow failure syndrome (Sourced from: https://clinicaltrials.gov/ct2/show/NCT03773393)
Mechanisms of Action: Cell Therapy
Novel Mechanism: No
Modality: Cell Therapy
Route of Administration: N/A
FDA Designation: Orphan Drug - Anemia|Anemia, Aplastic *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Cellenkos
Company Location:
Company CEO:
Additional Commercial Interests: None
Clinical Description
Countries in Clinic: United States
Active Clinical Trial Count: 1
Recent & Upcoming Milestones
Highest Development Phases
Phase 1: Bone Marrow Diseases|Pancytopenia
Trial ID |
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|---|
NCT03773393 |
CK0801-101-1 | P1 |
Active, not recruiting |
Pancytopenia|Bone Marrow Diseases |
2027-05-25 |
50% |
2025-04-15 |
Primary Completion Date|Primary Endpoints|Study Completion Date|Treatments |